Alternative Therapy for Lung Cancer: High Dose Vitamin C

​

​

Case study report date: 10/04/2025 - By Dr Hamad.

​

Patient information: A 80 year old man. 91 kgs in weight. Attended Leicester Ozone Clinic in the period from 08 Jul 2024 to 13 Aug 2024. 

​

Main symptoms at presentation: 

• Prostate cancer which spread to the lymph nodes and the pelvic bones.

• Presented with increasing pain in spine and legs and in the 2 months before coming to the clinic he experienced pain and swelling in the right leg. 

• Blood in urine from time to time but no obstruction symptoms. 

​​

Past illnesses: 

• 2015 ca colon, had surgery, hemicolectomy.

• Fibromyalgia.

• Haemochromatosis.

• Celiac disease.

​

Prescription medication: 

• None.

​

Diet and supplements: Vegetarian. On multivitamin supplements.

​

COVID-19 vaccination status: Unvaccinated.

​

Timeline of Events and therapies received prior to attending Leicester Ozone Clinic:

• Exact date unknown: Prostate cancer was diagnosed many years ago (exact date unknown) but he did not agree to therapy offered from NHS oncology so not under follow up from hospital since 2022.

​

Therapy received from Leicester Ozone Clinic and therapeutic response: ​

• 24 June 2024: A pre-therapy blood test was taken, the Prostate Specific Antigen (PSA) was 8845 ng/ml (upper limit of normal for his age is 6.5 ng/ml). haemoglobin 121 g/L (normal range 130 - 170).

• 8 Jul 2024: Started high dose vitamin c from Leicester Ozone Clinic, the first dose was 20 gram then all subsequent doses were 40 grams. He received a total of 10 doses at a twice weekly frequency, which continued until 13 Aug 2024.  Each infusion was followed by 1 -2 days of bleeding in urine. With subsequent doses the bleeding started to affect him by feeling more and more lethargic and unsteady on his legs. 

• 05 August 2024: PSA level is 4800 ng/ml Haemoglubin is 68 g/L. ​

• 13 August 2024: A decision to stop the vitamin c infusions was made as a result of ongoing urine bleeding after each infusion and declining level of haemoglubin. The patient was clinically deteriorating despite decreasing level of PSA. We continued with haemoglobin and PSA monitoring. 

• 02 Sept 2024: PSA level is 7135.2 ng/ml and Haemoglubin is 86 g/L. 

• 22 Oct 24: PSA has dramatically reduced to 97.95 ng/ml despite cessation of therapy over 2 months before and his Haemoglubin improved to 92 g/L. He felt better in himself.

• November 2024: The patient sustained a fall at home and he was taken to hospital where he was subsequently moved to a nursing home for palliative care.  

​